DSNKY (Daiichinkyo Co) Total Liabilities : $12,295 Mil (As of Mar. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Daiichinkyo Co Total Liabilities?

Daiichinkyo Co's Total Liabilities for the quarter that ended in Mar. 2025 was $12,295 Mil.

Daiichinkyo Co's quarterly Total Liabilities increased from Sep. 2024 ($11,712.35 Mil) to Dec. 2024 ($11,827.50 Mil) and increased from Dec. 2024 ($11,827.50 Mil) to Mar. 2025 ($12,295.27 Mil).

Daiichinkyo Co's annual Total Liabilities increased from Mar. 2023 ($7,953.02 Mil) to Mar. 2024 ($11,831.19 Mil) and increased from Mar. 2024 ($11,831.19 Mil) to Mar. 2025 ($12,295.27 Mil).

Daiichinkyo Co Total Liabilities Historical Data

The historical data trend for Daiichinkyo Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Total Liabilities Chart

Daiichinkyo Co Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Total Liabilities

Get a 7-Day Free Trial

7,480.51

7,341.45

7,953.02

11,831.19

12,295.27

Daiichinkyo Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															11,831.19	-	11,712.35	11,827.50	12,295.27

Daiichinkyo Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Daiichinkyo Co's Total Liabilities for the fiscal year that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5058.662	+	(677.141	+	6549.005
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	10.459	+	0)
	=	12,295

Total Liabilities	=	Total Assets (A: Mar. 2025 )	-	Total Equity (A: Mar. 2025 )
	=	23186.466	-	10891.199
	=	12,295

Daiichinkyo Co's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5058.662	+	(677.141	+	6549.005
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	10.459	+	0)
	=	12,295

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	23186.466	-	10891.199
	=	12,295

Daiichinkyo Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

DSKYF:USA 4568:Mexico 4568:Japan D4S:Germany

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.